91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The requirements for global HTA/reimbursement consideration have changed and are continuing to evolve in response to the current pandemic. This considers how drug sponsors can navigate a path to reimbursement success and market access for drugs that were in development prior to the pandemic.
-
on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
conducted by 91黑料's Health Economics team and Bristol-Myers Squibb evaluates a cost-effective new treatment for melanoma patients in Japan.
-
Managed access programmes (MAPs) are often unfamiliar territory for clinical teams, as their purpose and regulatory environment are very different from randomised controlled trials. 91黑料's Veronica Gutierrez Martinez considers how .
-
91黑料's Richard Pitman joins global public health experts to address .
-
A patient insight article on .
-
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange.
-
-
An article featuring expert commentary from 91黑料's Gretchen Goller on .
-
that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
